Supplemental Figure 1 Baseline T-cell subset quantities. Significance testing of early-stage against metastatic TNBC cohorts is by t-test. Significance testing within cohorts is by the Kruskal-wallis method. HR+HER2-, hormone receptor positive, HER2-neu negative; HER2+, HER2-neu positive; eTNBC, early stage TNBC; Naive, chemotherapy-naive; >12 mo, >12 months since last chemotherapy; 6-12 mo, 6-12 months since last chemotherapy; Treg, regulatory T cell; CM, central memory; EM, effector memory; EMRA, effector memory cells re-expressing CD45RA